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G protein-coupled receptors control a wide range of physiological processes and are the target for many
clinically used drugs. Understanding the way in which receptors bind agonists and antagonists, their
organisation in the membrane and their regulation after agonist binding are important properties which
are key to developing new drugs. One way to achieve this knowledge is through the use of ﬂuorescent
ligands, which have been used to study the expression and function of receptors in endogenously
expressing systems. Fluorescent ligands with appropriate imaging properties can be used in conjunction
with confocal microscopy to investigate the regulation of receptors after activation. Alternatively,
through the use of single molecule microscopy, they can probe the spatial organisation of receptors
within the membrane. This review focuses on the techniques in which ﬂuorescent ligands have been
used and the novel aspects of G protein-coupled receptor pharmacology which have been uncovered.
This article is part of the Special Issue entitled ‘Fluorescent Tools in Neuropharmacology’.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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The membrane bound G protein-coupled receptors (GPCRs) are
the largest family of proteins in the human genome and mediate a
wide range of biological processes (Bockaert and Pin, 1999). Due to
their integral membrane location, they allow the transmission of a
signal from the outside of a cell to the intracellular environmentr Ltd. This is an open access articlthrough the binding of an agonist, such as a neurotransmitter or
hormone. Agonist binding causes conformational changes in the
receptor which leads to the direct activation of intracellular sig-
nalling proteins (e.g. GTP binding proteins, b-arrestins) which in
turn can trigger numerous downstream signalling cascades. The
role that GPCRs play in regulating a multitude of cellular responses
and their tractability as membrane proteins has led to this receptor
family being one of the most successful drug targets, with the most
recent estimates ascribing 26% of currently approvede under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. A schematic representing the range of techniques in which ﬂuorescent ligands can be used to investigate GPCR molecular pharmacology. The centre panel shows an example
ﬂuorescent ligand (CA200645) highlighting the pharmacophore, ﬂuorophore and linker regions. Laser scanning confocal microscopy (A) uses an adjustable pinhole to allow high
resolution imaging. A laser beam passes through the pinhole aperture, is reﬂected off a dichromatic mirror and then focused via the objective onto a single focal plane of the
ﬂuorescent specimen. Both in focus and out of focus ﬂuorescence emitted from the specimen travels back through the objective, to a detector pinhole. In focus light is focused
through the detector pinhole, where it is detected by the photomultiplier, whereas extraneous out of focus light is largely not. Automated confocal platereaders (B) allow high
content imaging to be performed on a higher throughput scale (6e1536 well plates) than that capable using manual confocal microscopy. Fluorescence correlation spectroscopy
(FCS) can be used to study the mobility of ﬂuorescently labelled moieties through a confocal volume of deﬁned dimensions of typically 0.25e0.5 ﬂ (C). Upon diffusing through the
confocal volume, ﬂuorescent molecules are excited (red star) and produce time dependent ﬂuctuations in ﬂuorescence. These can be analysed in a time dependent manner using
autocorrelation analysis to provide information on the mobility and concentration of ﬂuorescent particles present within the confocal volume. Total internal reﬂection ﬂuorescence
microscopy (TIRF-M) exploits the difference in refractive indices of two different mediums (in this case glass and the specimen) to minimise background ﬂuorescence and provide
single molecule sensitivity (D). When light hits this interface at a speciﬁc angle (termed the critical angle) it results in the incident light being totally internally reﬂected generating
an evanescent wave. The evanescent wave penetrates only typically 100 nm into the sample and decays exponentially with distance from the interface (shown by blue shading),
allowing the selective excitation of ﬂuorophores in thin cellular regions close to the interface (eg. basal membranes). Fluorescence activated cell sorting (FACS) allows the sorting of
heterogenous cell mixtures based on their ﬂuorescence properties (E). A suspension of cells is forced through a column, at a single cell per droplet ﬂow, whereby they pass through a
laser beam. Scattered and ﬂuorescent light is ﬁltered and detected (detector 1 and 2), with cells separated into distinct populations allowing the relative amount of bound ligand to
be determined. Time resolved ﬂuorescence resonance energy transfer (TR-FRET) can be used to investigate the molecular interactions of, in this example, ﬂuorescently labelled
GPCRs and ﬂuorescent ligands in living cells (F). Close proximity of ﬂuorescent ligand and receptor, facilitates the transfer of energy between donor (blue circle) and acceptor (red
star) ﬂuorophores (FRET; black lightning arrow). Donor or acceptor ﬂuorophores can be attached to either the receptor or ligand of interest. In TR-FRET, lanthanides are used as
donor ﬂuorophores as their long emission lifetime allows measurements to be made following a time delay which increases sensitivity, minimises the impact of background
ﬂuorescence and allows the technique to be used in situ.
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success, these drugs only target around 30% of non-olfactory GPCRs
which leaves over 70% as potential targets for novel pharmaceuti-
cals, many of which have been implicated in disease pathology
(Garland, 2013). There is a growing sense that screening of millions
of compounds at a given GPCRmay not be themost effective way of
identifying new candidate molecules, but rather that understand-
ing the unique pharmacology of an unmodiﬁed receptor in its
native environment has a greater potential to lead to more efﬁcient
drug discovery programmes.
One way to study unmodiﬁed GPCRs in their native cellular
environment is through the use of ﬂuorescent techniques, in
particular ﬂuorescent agonists or antagonists that bind selectivity
to the receptor of interest. Fluorescent ligands have been developed
for a wide range of peptide and non-peptide GPCRs and generallyconsist of an agonist or antagonist molecule conjugated via a linker
to a ﬂuorescent moiety. It has generally proved to be more chal-
lenging to generate non-peptide ﬂuorescent ligands due to their
relatively small molecular weight, which is substantially increased
by the attachment of a linker and ﬂuorophore.
This review will focus on describing the novel aspects of phar-
macology that can be probed by using ﬂuorescent ligands and
relate this to the function that they are able to reveal. The main
techniques discussed in this review are depicted in Fig. 1. The ex-
amples below are not intended to be an exhaustive list of ﬂuores-
cent ligands that have been used to study receptor pharmacology,
which have been described comprehensively in a recent review
(Sridharan et al., 2014), but it will detail their advantages and use
examples from the literature in which they shine new light on the
function of particular GPCRs.
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Fluorescent ligands for GPCRs are generated by taking a phar-
macophore, which is usually a known agonist or antagonist for the
receptor of interest, and conjugating it to a small organic ﬂuo-
rophore (Briddon et al., 2011). Although many different ﬂuo-
rophores have been effectively used to generate useful ﬂuorescent
ligands themain classes of ﬂuorophores used have been the BODIPY
series (Allen et al., 2000; Baker et al., 2011;Dalyet al., 2010; Tomasch
et al., 2012b; Vernall et al., 2012), the Alexa series (Arttamangkul
et al., 2000; Brand et al., 2008; Corbani et al., 2011; Morishima
et al., 2010) and rhodamine derivatives (Castro et al., 2005; Daly
et al., 2010; Guo et al., 2012). Fluorescent ligands containing these
ﬂuorophores have been effectively used in many of the techniques
detailed below with the exception of certain time-resolved
ﬂuorescence resonance energy transfer (TR-FRET) studies in which
europium linked ﬂuorescent ligands were developed to provide a
signal with a long ﬂuorescence lifetime (Albizu et al., 2010). For
many peptide based ﬂuorescent ligands, amine- or thiol-reactive
ﬂuorophores can be directly coupled to the peptide ligand via
reactive lysine or cysteine amino acid side chains (Arttamangkul
et al., 2000; Harikumar et al., 2006). For small molecule ligands,
however, a linker is generally required to separate the pharmaco-
phore from theﬂuorophore to allowaccess of the pharmacophore to
the transmembrane orthosteric binding site. The composition and
length of this linker can have major effects on both the pharmaco-
logical, physicochemical and photophysical properties of the
resulting ﬂuorescent ligands (Baker et al., 2010, 2011; Vernall et al.,
2013). In addition, these properties are also heavily inﬂuenced by
the choice of ﬂuorophore which can change ﬂuorescent ligand af-
ﬁnity, photophysics and lipid solubility (Baker et al., 2010; Vernall
et al., 2013). For these reasons, each new ﬂuorescent ligand, both
peptide and small molecule, must be considered as a completely
new pharmacological entity compared to the parent ligand and be
fully characterised before use in further studies. Comprehensive
reviews on ﬂuorescent ligands for GPCRs have recently been pub-
lished which contain the structures of many of the ligands
mentioned below as it beyond the scope of the present review to
discuss the chemistry behind thesemolecules in detail (Kozma et al.,
2013; Kuder and Kiec Kononowicz, 2014; Vernall et al., 2014).
2.1. Fluorescent ligands as alternatives to radioligands in
competition binding assays
The initial step in the identiﬁcation of a newdrug-likemolecule for
a GPCR is to determine its afﬁnity at the receptor of interest. This isFig. 2. Visualisation of competition binding at the adenosine-A3 receptor. (A) Adenosine-A
concentrations of antagonist A (left hand panel) or antagonist B (right hand panel) in trip
images were obtained per well and the montage images shown represent all the images c
generated that correspond to the data obtained in A.often achieved by monitoring binding of a radiolabelled receptor
ligand, butdue to thedisposal and safetyconcerns surrounding theuse
of large quantities of radiochemicals an alternative to these assays has
been sought. Fluorescent ligands are a viable solution to this issue as
they can be used inmanyof the sameways as radioligands. There have
beenvarious attempts todevelop assays that useﬂuorescent ligands to
determine the afﬁnity of unlabelled ligands and these have been
reviewedpreviously (Cottetet al., 2011). Thesehave included theuseof
ﬂuorescence resonanceenergy transfer (FRET) techniques (Zwieret al.,
2010),ﬂuorescencepolarisation (Allenet al., 2000) andﬂowcytometry
(Young et al., 2005). More recently, a method has been described for
the adenosine-A1 and -A3 receptors in which the binding of the ﬂuo-
rescent ligand, CA200645, to the receptorwasmeasureddirectly using
automated confocal imaging (Stoddart et al., 2012). The CA200645
ligand consists of the non-selective adenosine receptor antagonist
xanthine amine cogener (XAC) linked to the red BODIPY630/650 ﬂu-
orophore via a b-alanine linker. To estimate the levels of ﬂuorescent
ligandbound toCHOcells expressing the adenosine-A1 or-A3 receptor,
a confocal imaging plate reader was used to automatically capture
images from a multi-well plate and the integrated ﬂuorescence in-
tensityof the resulting imageswasused as ameasure of ligandbinding
(Fig. 2). This assay was also capable of detecting the binding of low
molecular weight fragments to both the A3 and A1 receptors (Stoddart
et al., 2012). Fragment-based drug discovery (FBDD) is becoming a
widely used tool in drug discovery as it often results in lead com-
pounds with a lower molecular weight and complexity than tradi-
tional methods (Hopkins et al., 2004). GPCR FBDD is often carried out
with biophysical techniques using puriﬁed receptors, therefore the
ability to carry out FBDD in live cells, and potentially in endogenously
expressing systems, may also help develop newmolecular entities for
targeting therapeutically importantGPCRs. In addition to screening for
fragment like ligands, ﬂuorescent ligands have been used for identi-
fying newmolecules for a range of GPCRs. For instance, Iturrioz et al.,
used aﬂuorescent ligand in a FRETbased systemwhich enable them to
identify the ﬁrst small molecule agonist for the apelin receptor which
may lead to newmolecules being developed for the treatment of heart
failure (Iturrioz et al., 2010). Also, in a ﬂow cytometry based system,
new non-peptide small molecule ligands for the formylpeptide re-
ceptor were identiﬁed from a library of 880 compounds using a ﬂuo-
rescein labelled formylmethionine-leucine-phenylalanine-lysine
(Young et al., 2005). This demonstrates that together with fragment
screening, ﬂuorescent ligands may be able to replace radioligands in
many of the early drug discovery processes.
The direct measurement of ﬂuorescent ligand binding has also
been used to characterise new antagonists at the adenosine-A1
and -A3 receptors. Using a ﬂuorescent antagonist that emits at3 receptor expressing CHO cells were treated with 25 nM CA200645 and increasing
licate and subsequently imaged on the ImageXpress Ultra confocal plate reader. Four
aptured. Images were subjected to image analysis and concentration response curves
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ﬁnity of ﬂuorescent antagonists emitting at red wavelengths and
vice versa (Vernall et al., 2013). Although the throughput of this
system is not as high as for FRET or ﬂuorescence polarisation assays
(Allen et al., 2000; Veiksina et al., 2014; Zwier et al., 2010), one
advantage of this imaging-based technique is the ability to simul-
taneously determine the afﬁnity and efﬁcacy of an unknown ligand
(Stoddart et al., 2012) and potentially to correlate this to what is
happening at the single cell level.
Fluorescent ligands can also be used over a much wider concen-
tration range than radiolabelled ligands and provide scope for deter-
mining binding to multiple conformational states. For example, the
ligand CGP 12177 is a b-adrenoceptor ligand that has been shown to
antagonise agonist-mediated responses at the high afﬁnity catechol-
amine binding site of the b1-adrenoceptor but also to have agonist
activity at higher concentrations through binding to a secondary low
afﬁnity receptor conformation (Baker et al., 2003;Konkar et al., 2000).
Useof aﬂuorescentderivativeof CGP12177 (BODIPY-TMR-CGP)over a
wide concentration range allowed the detection and characterisation
of both sites at the b1-adrenoceptor (Gherbi et al., 2014).Fig. 3. Comparison of ﬂuorescent ligands with and without high levels of non-speciﬁc bind
BY630 (pKD ¼ 7.5) (top panels) (Briddon et al., 2004) or 0.5 nM XAC-Ala-Ser-X-BY630 (pKD ¼
or presence (right hand panels) of 100 nM MRS1220 to inhibit speciﬁc receptor binding. A
ligands were chosen to give 50% occupancy in both cases. Images were obtained using Zeiss L
ﬂuorescence in the absence of unlabelled antagonist. XAC-X-BY630 shows high levels of in
little non-speciﬁc ﬂuorescence in MRS1220-treated cells incubated with XAC-Ala-Ser-X-BY63
for power offset and gain.3. Use of ﬂuorescent ligands to study receptor expression
patterns
3.1. Required properties of a ﬂuorescent ligand
One obvious, but challenging, use of ﬂuorescent GPCR ligands is
in conjunction with microscopy to study the cellular and tissue
localisation of a receptor. Many of the studies detailed below use
confocal microscopy to obtain images. Confocal microscopy uses a
laser to illuminate the sample coupled with a pinhole to eliminate
out of focus light which allows a single plane of the sample to be
visualised. To perform useful microscopy studies, a ﬂuorescent
ligand for a GPCR needs to show discrete plasma membrane
binding which can be blocked by an unlabelled ligand, and low
levels of non-speciﬁc binding (including intracellular ﬂuorescence).
There are many examples in the literature of ﬂuorescent ligands
with good imaging properties, including those for the vasopressin
and oxytocin receptors (Corbani et al., 2011), kappa opioid receptor
(Houghten et al., 2004), b2 adrenergic receptor (Baker et al., 2011),
adenosine-A3 receptor (Stoddart et al., 2012) and the leukotriene B4ing. CHO cells expressing the adenosine-A3 receptor were treated with 30 nM XAC-X-
9.3) (bottom panels) (Vernall et al., 2013) for 30 min in the absence (left hand panels)
pproximate KD (values taken from Vernall et al., 2013) concentrations of each of the
SM510 Meta NLO confocal microscope. Both ligands showmembrane localisation of the
tracellular ﬂuorescence in the presence of unlabelled antagonist whereas there is very
0. All images shownwere obtained on the same day with identical microscope settings
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focused on the development of ﬂuorescent ligands for the adeno-
sine receptors with improved imaging properties. We found that
inclusion of a peptidic linker in an XAC-BODIPY630/650 conjugate
improved its afﬁnity and signiﬁcantly reduced the levels of intra-
cellular non-speciﬁc binding (Vernall et al., 2013) compared to a
direct XAC-BODIPY630/650 (XAC-X-BY630) conjugate (Fig. 3)
(Briddon et al., 2004). Their improved afﬁnity also allowed them to
be used at lower concentrations with the same degree of receptor
occupancy which is beneﬁcial in reducing levels of non-speciﬁc
binding. Developing a new ﬂuorescent ligand for a GPCR often fo-
cuses on retaining the high afﬁnity of the parent pharmacophore.
However, high afﬁnity per se does not necessarily mean that the
resulting ﬂuorescent ligand will be optimal for imaging studies. For
example, a ﬂuorescent ligand for the histamine-H1 receptor
(mepyramine-X-BY630) displayed similar afﬁnity for the receptor
as the parent ligand mepyramine but showed very high levels of
non-speciﬁc binding which prevented its use in confocal imaging
studies (Rose et al., 2012).
3.2. Use of ﬂuorescent ligands in endogenous systems
Once a ﬂuorescent ligand has been shown to have appropriate
imaging properties it can be used to probe the expression pattern of
the receptor in natively expressing systems. Morishima and co-
workers demonstrated the discrete localisation of the ﬂuores-
cence to the muscle layer of human prostate using a ﬂuorescent a1B
adrenergic receptor antagonist (Morishima et al., 2010). Similarly,
using a ﬂuorescent antagonist for the prostanoid EP3R, it was
shown that the EP3Rwas expressed inmurine kidney and in human
brain tissue (Tomasch et al., 2012a). In T lymphocytes, a CXCL12
based ﬂuorescent ligand has been used in conjunction with both
microscopy and ﬂow cytometry to identify CXCR4 positive T-
lymphoid SupT1 cells (Hatse et al., 2004) and expression of the CB2
receptor on CD4þ T cells was demonstrated using a ﬂuorescent
ligand for the cannabinoid CB2 receptor (Petrov et al., 2011). For the
neuropeptide Y1 receptor (Y1R), the development of a small
molecule ﬂuorescent antagonist allow the conﬁrmation of the
expression of the receptor in a human breast cancer cell line (MCF-
7) and interestingly using ﬂow cytometry they showed that they
could measure the afﬁnity of unlabelled antagonists in a eryth-
oleukemia cell line that endogenously expresses the Y1R (Schneider
et al., 2007). Daly et al. (2010) simultaneously used three spectrally
discrete ﬂuorescent ligands to investigate the distribution of a-
adrenoceptors, b-adrenoceptors and the cannabinoid-like receptor,
GPR55, in mouse arteries at the level of single cells (Daly et al.,
2010). They showed that in mouse vascular smooth muscle there
was a heterogeneous expression of all three receptor subtypes, with
some cells expressing all three receptors and others expressed only
the a1-and b-adrenoceptors. In contrast, they also demonstrated
the colocalisation of a1 adrenoceptors and GPR55 within the
mesenteric arteries (Daly et al., 2010). There are three a1-adreno-
ceptor subtypes (a1A, a1B and a1D) and the localisation of these
subtypes have been studied using the a non-selective ﬂuorescent a1
receptor antagonist BODIPY-FL-prazosin (QAPB) in the arteries of
mice. Using QAPB in a1A/B, or a1B/D knock-out mice differences in
the localisation of a1A, and a1D subtypes in mesenteric and carotid
arteries were found (Methven et al., 2009a, 2009b). Additionally, it
was shown that the a1D receptor is found both at the cell surface
and intracellularly, and this has been proposed to play in a role in
the observed pharmacology of this receptor (Methven et al.,
2009b). A ﬂuorescent derivative of the parathyroid hormone
(PTH) has been used to visualise the expression of the PTH receptor
in the proximal tubule of mice kidneys. The authors extended the
use of this ﬂuorescent ligand to show the colocalisation of thereceptor with scaffold proteins such as ezrin and interestingly
demonstrated that the expression pattern of the receptor changes
upon hyperparathyroidism (Guo et al., 2012). These studies
demonstrate the power of ﬂuorescent ligands to improve our un-
derstanding of the expression pattern of receptor subtypes and
their potential for interactions. Fluorescent ligands can also shed
light on unknown functions of receptors. This has been recently
demonstrated for the adenosine-A3 receptor (Corriden et al., 2013)
again through the use the ﬂuorescent adenosine receptor antago-
nist, CA200645. Confocal microscopy demonstrated that the A3
receptor was highly enriched in microdomains of human neutro-
phils which were at the base of membrane projections which the
authors showed were involved in the long-range capture of path-
ogens. Furthermore, the presence of an adenosine receptor agonist
increased the number of these projections demonstrating a previ-
ously unknown role of the A3 receptor in neutrophil function
(Corriden et al., 2013).
3.3. Studying receptor internalisation using ﬂuorescent ligands
Many GPCRs are known to internalise in response to agonist
exposure, and ﬂuorescent agonists for GPCRs can also internalise
receptors or result in clustering of the ﬂuorescent ligand occupied
receptors within the cell and on the cell membrane, as demon-
strated for the m and d opioid receptor (Arttamangkul et al., 2000)
adenosine-A2A receptor (Brand et al., 2008), AT1 angiotensin re-
ceptor (Hunyady et al., 2002) and neuropeptide Y1 receptor
(Ziemek et al., 2006) heterologously expressed in non-natively
expressing systems. More excitingly, this opens up the possibility
of visualising reorganisation and regulation of endogenously
expressed GPCRs. Arttamangkul and co-workers, for instance,
extended the use of their ﬂuorescent agonist (Arttamangkul et al.,
2000) to study the internalisation and desensitisation of endoge-
nously expressed m opioid receptor in a primary cell line derived
from mouse locus coeruleus neurones (Arttamangkul et al., 2006).
They demonstrated that in these cells the ﬂuorescent agonist
induced receptor clustering and internalisation, and that by
blocking this internalisation with concanavalin A the decrease in
membrane potential induced by receptor activation still underwent
desensitisation thus showing that receptor internalisation of the m
opioid receptor is not a pre-requisite for desensitisation
(Arttamangkul et al., 2006). There are still many unanswered
questions regarding receptor internalisation and the termination of
the agonist signal with recent reports showing that an internalised
receptor can continue to signal (Calebiro et al., 2010; Irannejad
et al., 2013, 2014). Fluorescent agonists may allow studies into the
exact timing of signal termination, and determine whether the
ligand remains bound to the receptor during the internalisation
process. The pathway which a receptor takes upon internalization
has been probed for the AT1 angiotensin receptor with a ﬂuorescent
derivative of the endogenous agonist AngII using confocal micro-
scopy. Using this ﬂuorescent agonist they showed that the receptor
localised with Rab5-positive early endosomes upon endocytosis
and then with Rab11-positive recycling endosomes and Rab7-
positive degradation lysosomes after long term agonist stimula-
tion. In addition, it was demonstrated that inhibition of PI3 kinase
prevented efﬁcient recycling of the receptor to the cell surface
(Hunyady et al., 2002). Localisation of a ﬂuorescent ligand with
endosomal markers has also been observed for the vasopressin V2
receptor (Chen et al., 2011) Within this special themed issue, we
have shown that a newly developed ﬂuorescent agonist for aden-
osine receptors, containing a peptidic linker, can induce internal-
isation of the adenosine-A3 receptor and co-localise with receptor/
arrestin3 complexes that have been trapped by biomolecular
ﬂuorescence complementation (Stoddart et al., 2015). These
L.A. Stoddart et al. / Neuropharmacology 98 (2015) 48e57 53examples demonstrate that it is possible to use ﬂuorescent ligands
to track the receptor/agonist complexes through multiple steps in
the internalisation process.
3.4. Ligand-receptor binding kinetics
An often overlooked characteristic of a GPCR ligand is its binding
kinetic parameters and it is becoming increasingly clear that the
residence time of a ligand on a receptor may inﬂuence its effec-
tiveness as a drug in the clinic (Vauquelin and Charlton, 2010).
Binding kinetics at a GPCR can be examined through radioligand
binding experiments or using biophysical techniques such as sur-
face plasmon resonance. Fluorescent ligands provide an alternative
to allow the study of kinetics in living cells, as demonstrated for the
adenosine-A1 and -A3 receptors (May et al., 2011; May et al., 2010)
and the histamine-H1 receptor (Schiele et al., 2014). May et al.
(2011) demonstrated that a ﬂuorescent agonist for the adenosine
receptors, ABA-X-BY630, could be used in conjunction with
confocal microscopy and a high ﬂow rate perfusion system to
accurately measure the kinetics of agonist binding in single living
cells. They further went on to show that allosteric modulators could
inﬂuence the dissociation rate of ABA-X-BY630 (May et al., 2010).
They also demonstrated the power of this technique to detect
functional effects of receptor oligomerisation by examining the
effect of orthosteric antagonists or agonists on the dissociation ki-
netics of the orthosteric ﬂuorescent ligand. Unexpectedly, the
presence of unlabelled orthosteric ligands increased the dissocia-
tion rate of ABA-X-BY630 from the adenosine-A3 receptor. This was
shown to be through the binding of low concentrations of the
ﬂuorescent ligand to one protomer of a receptor homodimer with a
second unlabelled ligand enhancing the dissociation rate of the
ﬂuorescent ligand acting with a high degree of negative coopera-
tivity across the dimer interface following binding to the second
protomer (May et al., 2011). This further demonstrates that ﬂuo-
rescent ligands can be used to study novel aspects of GPCR
pharmacology.
4. Fluorescent ligands to probe receptor organisation in the
membrane
In addition to thewell characterised use of ﬂuorescent ligands to
identify the expression and localisation of receptors, they can be
used in single molecule microscopy experiments (e.g., total internal
reﬂection microscopy, TIRF-M; ﬂuorescence correlation spectros-
copy, FCS) to quantify the real time mobility of receptoreligand
complexes in living cells, as a way of probing how the receptor is
organised at the molecular level within the membrane.
FCS measures the diffusion of ﬂuorescently labelled molecules
through a small deﬁned confocal volume, typically of ~0.25 fL
(0.2  1 mm) (Ries and Schwille, 2012). As ﬂuorescent particles pass
through this volume, they produce time-dependent ﬂuctuations in
intensity, whose frequency can be analysed using autocorrelation
analysis to provide information about their mobility and concen-
tration (Briddon and Hill, 2007). The detection volume used in FCS
encompasses a cellular region containing only ~0.2 mm2 of plasma
membrane and typically contains 1e100 ﬂuorescent particles.
GPCRs have been shown to be spatially organised at the plasma
membrane into discrete microdomains, through interactions with
the cytoskeleton or the lipid environment (Cordeaux et al., 2008;
Insel et al., 2005; Padgett et al., 2010) which may organise intra-
cellular signalling components in close proximity (Corriden et al.,
2014) and place barriers on the extent of lateral diffusion possible
(Daumas et al., 2003; Suzuki et al., 2005). It is therefore likely that
the membrane region contained within the confocal volume is
heterogeneous in respect to receptor expression, addingcomplexity to the identiﬁcation of speciﬁc receptor complexes (He
and Marguet, 2011). However the use of ﬂuorescent ligands with
FCS can elucidate the molecular composition of signalling com-
plexes due to the marked difference in molecular weight, and
therefore diffusion characteristics, of free and receptor bound
ligand, which can be deconvolved by autocorrelation analysis
(Briddon and Hill, 2007). Since the amplitude of the autocorrelation
curve is inversely proportional to the concentration of ﬂuorescent
particles present within the confocal volume, this means that FCS is
best suited to low concentrations of ﬂuorescent ligand or receptor,
and is therefore sensitive enough to be used where receptor
expression is low (such as in native tissues) (Briddon and Hill, 2007;
Diekmann and Hoischen, 2014).
Fluorescent ligands have been shown to freely diffuse in three
dimensions with a typical dwell time in the FCS detection volume
of between 50 and 100 ms (Briddon and Hill, 2007). However,
interaction of ﬂuorescent ligands with membrane bound receptors
results in amarked slowing of their diffusion, since the receptor has
a much larger molecular weight and is conﬁned within a cell
membrane. As autocorrelation functions of ﬂuorescent species are
additive, when the measurement volume contains both free and
bound ligand, the autocorrelation curves produced consist of
multiple components with differing dwell times (and hence diffu-
sion coefﬁcients). The fast moving component, termed tD1, is
representative of free ﬂuorescent ligand, whereas one or more
slower moving components represent ligand-receptor complexes
(termed tD2 and/or tD3 respectively). To date, FCS in combination
with ﬂuorescent ligands has been used to characterise the hista-
mine-H1 receptor (Rose et al., 2012), b2-adrenoceptor (Hegener
et al., 2004; Prenner et al., 2007), galanin receptor (Pramanik
et al., 2001), somatostatin receptor (Grant et al., 2004) and the
adenosine-A1 (Briddon et al., 2004; Middleton et al., 2007) and -A3
(Cordeaux et al., 2008; Corriden et al., 2014) receptors. In all of
these studies ligand-receptor complexes were shown to exist in
two distinct diffusing components at the plasma membrane
(designated tD2 and tD3), suggesting at least two states or pop-
ulations of receptors exist. Dwell times for these components
typically ranged from 1 to 20 ms for tD2 and 10 to 700 ms for tD3
(see Table 1). Interestingly, the proportion of tD2 or tD3 represented
in the total fraction signiﬁcantly differs between receptor types
(Table 1).
Furthermore, the tD3 components detected have been proposed
to represent different conformations of the ligand-receptor com-
plex depending on the nature of the ﬂuorescent ligand (agonist or
antagonist) used (Briddon and Hill, 2007; Corriden et al., 2014). For
example, labelling with either ﬂuorescent agonist (ABEA-X-BY630;
Cordeaux et al., 2008) or antagonist (CA200645; Corriden et al.,
2014) has been shown to differentially identify the high afﬁnity
active (R*) and inactive (R) forms of the adenosine-A3 receptor
which can be tracked by the characteristics of the tD3 component.
The low concentration of ﬂuorescent ligands used in FCS would
promote selective labelling of these different high afﬁnity confor-
mations. Additionally, the faster diffusing tD2 component in these
experiments has been postulated to represent a receptor state
where the ﬂuorescent ligand has dissociated during the time taken
for the complex to transit through the confocal volume (Corriden
et al., 2014). It is also worth considering, however, that both tD2
and tD3 may not represent distinct receptor states, but are rather a
composite of diffusion coefﬁcients consisting of multiple ligand-
receptor complexes (Briddon and Hill, 2007) which may reﬂect
the range of ligand speciﬁc conformational states proposed for
GPCRs (Seifert, 2013).
Additionally, many of the diffusion rates observed for tD3
derived from autocorrelation analysis are too slow to represent
single receptor species implying the formation of macromolecular
Table 1
Summary of the use of ﬂuorescent ligands at GPCRs in ﬂuorescence correlation spectroscopy (FCS) experiments.
The distinct diffusion components of ligand-receptor complexes derived from the autocorrelation curve are stated as tD2 and tD3. The dwell time of these components within
the confocal volume are stated (in ms). The percentage fraction of each component of the total (tD2 and tD3) is also shown. All values stated are taken from those published or
have been estimated from published diffusion coefﬁcients using the equation tD ¼ r2/4D, where r is the beam radius of the confocal volume, and D the published diffusion
co-efﬁcient.
Cell type Receptor Ligand Activity tD2 dwell
time; ms
tD2
fraction; %
tD3 dwell
time; ms
tD3 fraction; % Ref
CHO K1 H1 Mepyramine BY630 Antagonist 5 25% 125 75% (Rose et al., 2012)
CHO K1 Adenosine A1 XAC-BY630 Antagonist 17 85% 320 15% (Briddon et al., 2004)
CHO K1 Adenosine A1 ABA-BY630 Agonist 8 48% 233 52% (Briddon et al., 2004)
CHO K1 Adenosine A1 ABEA-BY630 Agonist 9 40% 267 60% (Middleton et al., 2007)
CHO K1 Adenosine A3 CA200645 Antagonist 8.7 40% 266 60% (Corriden et al., 2014)
CHO K1 Adenosine A3 ABEA-X-BY630 Agonist 6 25% 131 75% (Cordeaux et al., 2008)
Rat neurones b2-adrenoceptor AF532-arterenol Agonist 2 78% 160 22% (Hegener et al., 2004)
Alveolar A549 b2-adrenoceptor AF532-arterenol Agonist 3 66% 45 33% (Hegener et al., 2004)
Rat C6 (glioma) b2-adrenoceptor AF532-noradrenaline Agonist 0.7 65% 9.4 35% (Prenner et al., 2007)
Rat RinmF
(pancreatic
insulinoma)
Galanin Rhodamine-galanin Agonist 22 88% 700 12% (Pramanik et al., 2001)
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signalling complexes (Corriden et al., 2014; Rose et al., 2012).
Additional indirect evidence for oligomerisation has also been
observed, with evidence for negative cooperativity across a dimer
interface observed from FCS washout experiments performed on
adenosine-A3 receptors labelled with the antagonist CA200645
and unlabelled competing agonist XAC (Corriden et al., 2014).
However relating changes in diffusion coefﬁcients derived from
autocorrelation analysis to changes in molecular mass, can often
be problematic due to the cube root relationship that exists be-
tween the two factors (Briddon and Hill, 2007). For example
whilst the formation of a GPCR dimer from a monomer is a 2-fold
change inmass, this only equates to a 1.25-fold change in diffusion
coefﬁcient. The use of photon counting histogram (PCH) analysis
may go some way to addressing this, as a doubling in mass (i.e.
monomer to dimer) theoretically results in a doubling in molec-
ular brightness, which is detectable (Herrick-Davis et al., 2013;
Muller et al., 2000). PCH analysis has been used for GPCRs tag-
ged with full length ﬂuorescent proteins (Herrick-Davis et al.,
2013; Kilpatrick et al., 2012) but as yet not been used with ﬂuo-
rescent ligands. FCS and other ﬂuctuation based techniques in
conjunction with ﬂuorescent ligands can therefore be used to
characterise populations of receptors within membrane micro-
domains, and FCS has provided important information on GPCR
mobility, activation and oligomeric states.5. Fluorescent ligands to study receptor dimerization
Oneway inwhich the organisation of receptors in themembrane
and receptor dimerization has been probed using ﬂuorescent li-
gands is TIRF-M. TIRF-M is a wide-ﬁeld imaging technique that can
excite ﬂuorescent molecules within a thin section of a sample. This
technique relies upon an evanescent wave being produced when
light is totally internally reﬂected at the boundary of twomediawith
different refractive indices (such as the glass/water interface
occurring at a coverslip). As the distance from this interface in-
creases, the intensity of this wave decays exponentially, meaning
that the region of the sample excited is limited to a few hundred
nanometres resulting in an improved signal to noise ratio (Fish,
2009). This sensitivity and restricted illumination depth makes
TIRF-M ideal for single molecule imaging and particularly for
tracking of individual receptors and receptor complexes over a
timescale of seconds to provide information on their mobility and
clustering (Hern et al., 2010). TIRF in conjunction with ﬂuorescent
ligands has been used to investigate the dynamics of GPCR oligo-
merisation in living cells. One advantage of this is that the resolutionof TIRF is sufﬁciently great enough to identify individual ﬂuorescent
ligand-receptor complexes, assuming a ligand is binding in a 1:1
stoichiometry. The labelled high afﬁnity muscarinic-M1 acetylcho-
line receptor antagonist, Cy3B-telenzepine, has been used in TIRF
studies to track and quantify the random walk lateral diffusion of
muscarinic-M1 receptors in the plasma membrane of CHO cells and
illustrated that the receptors can exist as monomers and transient
dimers (Hern et al., 2010). Interestingly dimers were found to only
make up approximately 30% of the total receptor population. Dual
colour labelling of receptors with both red (Cy3B) and green
(Alexa488) telenzepine ligand in a 1:1 ratio revealed the kinetics of
M1 receptor dimer association and dissociation to be a dynamic
process with a dimer half-life of 0.5 s. Similar results have also been
observed for N-formyl peptide receptors identiﬁed using an agonist
peptide conjugated to Alexa594, whereby at physiological receptor
expression levels, rapid association of monomers into dimers
(occurring every 150 ms) and dissociation of dimers (every 91 ms)
was observed with the equilibria of these processes fully charac-
terised for the ﬁrst time (Kasai et al., 2011). GPCR complexes with
different organisational and dynamic properties have also been
identiﬁed using SNAP-tag approaches (Calebiro et al., 2013). Inter-
estingly there are suggestions that the predominant receptor form
may also be inﬂuenced by receptor expression levels with dimers
the prevalent form at high receptor expression (although the dimer
lifetime is unaffected), most likely due to greater receptor proximity
increasing the likelihood of associations (Kasai and Kusumi, 2014).
TIRF in combination with ﬂuorescent ligands can therefore be used
to identify and track the mobility of receptor complexes in living
cells at a single molecule resolution. It has given valuable informa-
tion on the extent of dimer formation and the dynamic nature of this
process in biologically relevant timescales.
Many of the above techniques used to investigate GPCR
dimerization rely on the direct monitoring of the ﬂuorescent li-
gands. An additional advantage of ﬂuorescent ligands is their
ability to be used in energy transfer techniques such as time
resolved ﬂuorescence resonance energy transfer (TR-FRET) which
has been used in both heterologous and endogenous expressing
systems to study receptor dimers. In TR-FRET, the donor ﬂuo-
rophore is based on a lanthanide label (such as europium or
terbium), which has a much longer ﬂuorescence lifetime
(50e100 ms), a pronounced Stokes shift between excitation and
emission maxima and multiple emission peaks, allowing it to be
used with a variety of acceptor ﬂuorophores (Albizu et al., 2010;
Cottet et al., 2012). This results in a time delay between the
excitation and emission signal allowing separation from the much
shorter-lived (1e10 ns) background ﬂuorescence from the sample
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to noise ratios (Cottet et al., 2012).
TR-FRET can be used to investigate interactions of ligands
binding to their cognate receptor such as for the growth hormone
secretagogue type 1A receptor in HEK293T cells (Leyris et al., 2011),
dopamine-D1-D5 receptor subtypes (Hounsou et al., 2014) and
vasopressin V2 receptor (Loison et al., 2012). Typically the lantha-
nide derivative is attached via a SNAP tag to the receptor where it
acts as a donor for a ﬂuorescently labelled ligand. TR-FRET obser-
vations between labelled ligands and vasopressin, oxytocin and
dopamine-D2 receptors have also provided evidence of negative
cooperativity across receptor dimer interfaces, which are compa-
rable to that seen for oxytocin receptors in native tissue (see
below). Other receptorereceptor interactions have also been
investigated using TR-FRET. Maurel et al. (2008) have used the
SNAP substrate to link europium and d2 (an HTRF-speciﬁc ﬂuo-
rophore developed by Cisbio) ﬂuorophores to the respective N
termini of a range of Class A and C GPCRs in order to probe
dimerisation (Maurel et al., 2008). Interestingly this study impliedTable 2
Advantages and limitations of ﬂuorescent ligand techniques.
Technique Advantages
Laser scanning confocal
microscopy (manual)
- Adjustable pinholes allow imaging in
minimising the detection of out of focus li
resolution of cellular structures (when com
microscopy).
- Imaging in both the xy and z plane
multidimensional views.
- A wide range of ﬂuorophores can be used.
Automated confocal
microscopy (platereader)
- Is capable of high throughput and hig
multiple assay formats (eg. 6e1536 well p
well).
- Simultaneous or sequential scanning possi
- Multiparameter analysis is possible, allow
qualitative and quantitative data. Automat
minimises experimenter bias.
Fluorescence correlation
microscopy (FCS)
- Capable of single molecule detection wit
region (typically representing an area of 0
- High sensitivity, therefore can be used wh
low (such as often observed in native tissu
- Small assays volumes and ligand concen
particularly advantageous where ligands a
- Multiple diffusion components can b
autocorrelation trace, providing quantitati
different ﬂuorescent complexes.
Total internal reﬂection ﬂuorescence
microscopy (TIRF-M)
- Capable of single molecule sensitivity; Goo
decreases out of focus and background ﬂu
increased z resolution.
- Illumination is restricted to cellular regio
minimising phototoxic damage and photo
for longer observation times.
- A large range of ﬂuorophores can be used.
- Can be readily combined with other micro
Time resolved ﬂuorescence resonance
energy transfer (TR-FRET)
- Can study cellular interactions in living ce
- The longer ﬂuorescence lifetime of lantha
used in standard FRET increases sensitivity
read after any interfering background ﬂuo
Additionally lanthanide lifetimes are not d
ﬂuorophore intensity/concentrations, mak
suitable for use in living specimens.
- Time resolution allows the distances betwe
and acceptor ﬂuorophores to be quantiﬁed
when compared to FRET.that GABAB receptors form ‘dimers of dimers’ (see also Calebiro et
al., 2013) and that the proportion of Class A GPCRs dimers formed
may differ with expression level again reiterating that this is likely
to be a dynamic process. A similar method using lanthanide-
labelled SNAP and Halo tags has facilitated the investigation of the
formation and pharmacological consequences of dopamine-D1 and
-D3 receptor homo and heterodimerisation (Hounsou et al., 2014).
Importantly, TR-FRET has been performed between differen-
tially labelled ﬂuorescent ligands in native tissue samples. For
instance, europium (donor) and Alexa647 (acceptor)-labelled li-
gands were used to identify oxytocin receptor oligomers in mem-
brane samples taken from lactating rat mammary gland tissue
(Albizu et al., 2010). Strong TR-FRET signals were observed with the
simultaneous addition of labelled selective antagonists, implying
close proximity of the two ﬂuorophores and indirectly the forma-
tion of oxytocin dimers. Positive cooperativity was also observed
indicating simultaneous occupancy by labelled antagonists for both
ligand binding sites of the dimer. Conversely weak TR-FRET signals
and efﬁcacies were observed with deferentially labelled agonists,Limitations
a single focal plane by
ght, allowing greater
pared to epiﬂuorescence
allows reconstruction of
- The use of a pinhole reduces the strength of the
signal.
- Still some limits to resolution (particularly
compared to techniques such as electron
microscopy).
- Time consuming in respect to acquisition and
analysis, with the risk for both of unintended
experimenter bias.
h content imaging using
lates; multiple sites per
ble.
ing the acquisition of both
ed analysis also
- Spatiotemporal limits to resolution when
compared to manual confocal microscopy;
typically can only use objectives with a lower
numerical aperture (eg. 0.8) leading to a loss of
resolution of ﬁner cellular structures.
- Can only be used with dry objectives, resulting in
a loss of resolution due to the decreased refractive
index of air (versus oil).
hin a deﬁned membrane
.1 mm2).
en receptor expression is
es).
trations are used. This is
re expensive.
e isolated within one
ve information on
- FCS is only able to detect mobile ﬂuorescent
species.
- Relatively low throughput, therefore is time
consuming in respect to data acquisition and
analysis.
- Autocorrelation analysis assumes that the plasma
membrane is in 2 dimensions, when some small
regions have a 3 dimensional architecture (such
as clathrin coated pits).
- Due to the nature of autocorrelation function, it is
difﬁcult to derive changes in mass from this
analysis alone. However combined use of PCH
analysis allows this limitation to be addressed.
d signal:noise ratio which
orescence resulting in
ns at the interface region
bleaching. This also allows
scopy techniques
- Imaging is limited to cellular regions close to the
coverslip (due to the depth of penetration into
the sample of the evanescent wave).
- Requires objectives with high numerical aperture
(>1.4NA) to produce the reﬂective angles
required for generating evanescent waves.
- Relatively low throughput.
lls in real time.
nides versus ﬂuorophores
and allows signals to be
rescence has decayed.
ependent on local
ing TR-FRET particularly
en the separation of donor
with greater accuracy
- Distance and orientation constraints exist for
maximum efﬁciency of energy transfer between
ﬂuorophores (typically 10 nm).
- To facilitate energy transfer, overlapping donor
emission and acceptor absorption spectra are
required. This can increase the risk of bleed
through ﬂuorescence.
- A donor of sufﬁciently high quantum yield is
required in order to minimise the inﬂuence of
quenching.
- Fluorescence lifetimes can be affected by local
environmental conditions such as pH which can
be difﬁcult to control during the assay.
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single protomer ligand binding site occupancy. The changes in
binding stoichiometry implied for agonist and antagonist ﬂuores-
cent ligands were used as evidence against TR-FRET being caused
by random ‘bystander’ interactions. TR-FRET is therefore not only
able to investigate ligand binding and the formation of GPCR di-
mers in heterologous cell lines, but has great enough sensitivity to
be used in native tissues. Additionally the nature of the pharma-
cophore used can probe the inﬂuence of cooperativity across the
dimer interface in more physiologically relevant conditions.6. Future directions and conclusions
The study of GPCRs using ﬂuorescent ligands has advanced
signiﬁcantly in the last ten years not just in the range of techniques
used but also in the rational design of ﬂuorescent ligands and the
mechanistic insights they have uncovered. Each of the techniques
available to use in conjunction with ﬂuorescent ligand have advan-
tages but also limitations and these are summarized in Table 2. The
wealth of structural information derived from crystal structures of a
wide range ofGPCRs and improved in silicomodelling (Kooistra et al.,
2014) will hopefully allow a greater understanding of how a ﬂuo-
rescent ligand interacts with a receptor andwhat role the linker and
ﬂuorophore plays in this interaction. This should also lead to
improved design of ﬂuorescent ligands with speciﬁc properties and
allow the selection of good ligandeﬂuorophore pairs to be deter-
mined prior to extensive and expensive chemical synthesis. Struc-
tural knowledge will also help in the development of ﬂuorescent
ligands for speciﬁc imaging techniques. For example, ﬂuorescent li-
gands have the potential to be useful in super-resolutionmicroscopy
but they require speciﬁc photophysical properties that are not
common to all ﬂuorophores. Super-resolution microscopy will also
help with understanding the spatial expression of GPCRs and func-
tional regulation inmore detail that can be determined with current
confocal microscopy (Jonas et al., 2014). In conclusion, ﬂuorescent
ligands have been used to study a wide range of aspects of GPCR
pharmacology andwith the growth in this ﬁeld theywill continue to
be a valuable asset in drug discovery and academic GPCR research.Acknowledgements
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